Middle East & Africa Long-Term Injectable Drug Delivery Market Size and Forecast (2021

Description

List of Tables

The Middle East and Africa Long-Term Injectable Drug Delivery Market is projected to reach US$ 369.7 Million by 2034, increasing from US$ 171.1 Million in 2025. The market is anticipated to expand at a CAGR of 8.9% from 2026 to 2034.

Executive Summary and Middle East and Africa Long-Term Injectable Drug Delivery Market Analysis:

The Middle East & Africa Long-Term Injectable Drug Delivery Market, segmented across Saudi Arabia, the UAE, South Africa, and the Rest of MEA, is witnessing gradual expansion as healthcare systems respond to the increasing burden of chronic diseases. Conditions such as diabetes, cancer, cardiovascular disorders, and autoimmune diseases require prolonged treatment and are creating greater demand for formulations that can provide controlled drug release over extended periods. Long-acting injectable therapies are particularly valuable because they can reduce administration frequency and help patients maintain treatment schedules more consistently.

The region's growing elderly population is another factor contributing to market development. Geriatric patients often manage multiple chronic conditions and may benefit from simplified treatment regimens that minimize frequent medication administration. In parallel, technological progress in pharmaceutical formulations is improving the performance of long-term injectable systems. Developments involving biodegradable polymers, microspheres, depot formulations, and controlled-release technologies are helping extend therapeutic duration while improving the safety and effectiveness of injectable products.

Healthcare infrastructure development in countries such as the UAE, Saudi Arabia, and South Africa is creating a more favorable environment for advanced drug delivery technologies. Government-led healthcare modernization programs, increasing medical expenditure, and greater access to specialty medicines are supporting adoption. Pharmaceutical manufacturers and distributors are also forming partnerships to improve product availability and strengthen regional supply networks.

Growing awareness among physicians, pharmacists, and patients regarding the advantages of reduced-frequency therapies is further supporting demand. As healthcare providers increasingly prioritize adherence, convenience, and long-term treatment outcomes, injectable delivery technologies are expected to gain greater relevance across the MEA region.

Strategic Insights

Middle East and Africa Long-Term Injectable Drug Delivery Market Segmentation Analysis:

By Formulation Packaging (Ready-to-Use), the Middle East and Africa Long-Term Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment dominated the market in 2025.

By Therapeutic Application, the market is categorized into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Others. Diabetes represented the largest segment in 2025.

By Route of Administration, the market is segmented into Subcutaneous, Intramuscular, Intravenous, and Others. The Subcutaneous segment held the leading position in 2025.

By Usability, the market comprises Disposable Injectors and Re-usable Injectors. Disposable Injectors accounted for the dominant share in 2025.

By End User, the market is divided into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. Pharmaceutical and Biopharma Companies represented the leading segment in 2025.

Market Report Scope

Middle East and Africa Long-Term Injectable Drug Delivery Market Outlook

The growing use of long-acting biologics and biosimilars in oncology and autoimmune disease management is creating new opportunities for long-term injectable drug delivery. Patients with chronic and debilitating conditions often require prolonged therapy, making treatment convenience and adherence important considerations. Extended-release injectable formulations can reduce the number of administrations required while maintaining therapeutic effectiveness, potentially addressing injection fatigue and inconsistent medication use.

Ustekinumab is an example of a long-acting biologic used for conditions including moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Following initial loading doses, the therapy can be administered subcutaneously at extended intervals. In oncology supportive care, pegfilgrastim provides prolonged granulocyte colony-stimulating factor activity and can be administered as a single subcutaneous injection during each chemotherapy cycle to help reduce the risk of febrile neutropenia in appropriate patients.

The development of biosimilars is further expanding access to long-acting biological therapies. Regulatory authorities have approved biosimilar versions of products such as pegfilgrastim and ustekinumab following assessments of their analytical characteristics, efficacy, safety, and immunogenicity. The availability of these alternatives can provide healthcare providers with additional treatment options while potentially reducing therapy costs.

The need for these technologies is reinforced by the rising incidence of chronic diseases and the growing emphasis on patient-centered healthcare. Long-acting therapies can simplify treatment schedules and support continuity of care, particularly where healthcare systems face resource limitations. Continued innovation in biologic formulations, biosimilars, and injectable delivery platforms is therefore expected to contribute to the development of oncology and autoimmune disease treatment across the MEA market.

Middle East and Africa Long-Term Injectable Drug Delivery Market Country Insights

By country, the Middle East and Africa Long-Term Injectable Drug Delivery Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. South Africa held the largest market share in 2025.

South Africa carries a substantial combined burden of infectious and noncommunicable diseases, creating significant demand for therapies that can provide reliable and sustained drug delivery. According to the International Diabetes Federation (IDF), diabetes affected approximately 2.32 million adults in South Africa in 2024, representing a prevalence of around 7.2% among people aged 20-79 years.

The country also has one of the world's largest HIV burdens. Statistics South Africa and UNAIDS estimates indicate that approximately 8.15 million people were living with HIV in 2025, representing about 12.9% of the total population and approximately 18.1% of adults aged 15-49. Cancer represents another major healthcare challenge, with GLOBOCAN data reporting more than 111,000 new cancer cases in 2022. Breast, prostate, and cervical cancers were among the most prevalent cancer types.

These disease patterns create opportunities for long-acting injectable therapies, including extended-duration antiretroviral treatments and biologic therapies used in oncology and autoimmune disease management. Reduced dosing frequency can be particularly valuable in high-burden healthcare environments by supporting adherence and simplifying treatment delivery.

A significant recent development is South Africa's planned 2026 introduction of twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis in selected high-incidence districts. The program is expected to target multiple provinces through public healthcare facilities, with government agencies and partners working to improve local access and supply. This development, alongside broader multi-month dispensing initiatives for HIV treatment, highlights the country's increasing focus on longer-duration therapies.

As South Africa continues strengthening its healthcare infrastructure and expanding access to advanced medicines, long-term injectable technologies are expected to become increasingly important for managing chronic infectious and noncommunicable diseases.

Middle East and Africa Long-Term Injectable Drug Delivery Market Company Profiles

Key companies operating in the Middle East and Africa Long-Term Injectable Drug Delivery Market include Terumo Corp, Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Schott AG, AptarGroup Inc, Becton Dickinson and Co, Owen Mumford Ltd, and SHL Medical.

Product Code: TIPRE00044023

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Long-Term Injectable Drug Delivery Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Middle East and Africa Long-Term Injectable Drug Delivery Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Long-Term Injectable Drug Delivery Market - Middle East and Africa Analysis

5.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue (US$ Million), 2021 - 2034
5.2 Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Forecast and Analysis

6. Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Analysis - by Formulation Packaging (ready-to-use)

6.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis by Formulation Packaging (ready-to-use)
- 6.1.1 Ampoules
  - 6.1.1.1 Overview
  - 6.1.1.2 Ampoules: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Vials
  - 6.1.2.1 Overview
  - 6.1.2.2 Vials: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.3 Cartridges
  - 6.1.3.1 Overview
  - 6.1.3.2 Cartridges: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.4 Bottles
  - 6.1.4.1 Overview
  - 6.1.4.2 Bottles: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Analysis - by Therapeutic Application

7.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis by Therapeutic Application
- 7.1.1 Diabetes
  - 7.1.1.1 Overview
  - 7.1.1.2 Diabetes: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Oncology
  - 7.1.2.1 Overview
  - 7.1.2.2 Oncology: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Auto-Immune Disorders
  - 7.1.3.1 Overview
  - 7.1.3.2 Auto-Immune Disorders: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Cardiovascular Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Cardiovascular Diseases: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Infectious Diseases
  - 7.1.5.1 Overview
  - 7.1.5.2 Infectious Diseases: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.6 Pain Management
  - 7.1.6.1 Overview
  - 7.1.6.2 Pain Management: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.7 Others
  - 7.1.7.1 Overview
  - 7.1.7.2 Others: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Analysis - by Route Of Administration

8.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis by Route Of Administration
- 8.1.1 Subcutaneous
  - 8.1.1.1 Overview
  - 8.1.1.2 Subcutaneous: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Intramuscular
  - 8.1.2.1 Overview
  - 8.1.2.2 Intramuscular: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Intravenous
  - 8.1.3.1 Overview
  - 8.1.3.2 Intravenous: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.4 Others
  - 8.1.4.1 Overview
  - 8.1.4.2 Others: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Analysis - by Usability

9.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis by Usability
- 9.1.1 Disposable Injectors
  - 9.1.1.1 Overview
  - 9.1.1.2 Disposable Injectors: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 9.1.2 Re-usable Injectors
  - 9.1.2.1 Overview
  - 9.1.2.2 Re-usable Injectors: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

10. Middle East and Africa Long-Term Injectable Drug Delivery Market Revenue Analysis - by End User

10.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis by End User
- 10.1.1 Pharmaceutical and Biopharma Companies
  - 10.1.1.1 Overview
  - 10.1.1.2 Pharmaceutical and Biopharma Companies: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 10.1.2 CMOs and CDMOs
  - 10.1.2.1 Overview
  - 10.1.2.2 CMOs and CDMOs: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

11. Middle East and Africa Long-Term Injectable Drug Delivery Market - Country Analysis

11.1 Middle East and Africa
- 11.1.1 Middle East and Africa Long-Term Injectable Drug Delivery Market Forecast and Analysis - by Country
  - 11.1.1.1 Saudi Arabia Market
    - 11.1.1.1.1 Saudi Arabia: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.1.2 Saudi Arabia: Middle East and Africa Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.1.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.1.2.2 Therapeutic Application
      - 11.1.1.1.2.3 Route Of Administration
      - 11.1.1.1.2.4 Usability
      - 11.1.1.1.2.5 End User
  - 11.1.1.2 South Africa Market
    - 11.1.1.2.1 South Africa: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.2.2 South Africa: Middle East and Africa Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.2.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.2.2.2 Therapeutic Application
      - 11.1.1.2.2.3 Route Of Administration
      - 11.1.1.2.2.4 Usability
      - 11.1.1.2.2.5 End User
  - 11.1.1.3 United Arab Emirates Market
    - 11.1.1.3.1 United Arab Emirates: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.3.2 United Arab Emirates: Middle East and Africa Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.3.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.3.2.2 Therapeutic Application
      - 11.1.1.3.2.3 Route Of Administration
      - 11.1.1.3.2.4 Usability
      - 11.1.1.3.2.5 End User
  - 11.1.1.4 Rest of Middle East and Africa Market
    - 11.1.1.4.1 Rest of Middle East and Africa: Middle East and Africa Long-Term Injectable Drug Delivery Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 11.1.1.4.2 Rest of Middle East and Africa: Middle East and Africa Long-Term Injectable Drug Delivery Market - By Segmentation
      - 11.1.1.4.2.1 Formulation Packaging (ready-to-use)
      - 11.1.1.4.2.2 Therapeutic Application
      - 11.1.1.4.2.3 Route Of Administration
      - 11.1.1.4.2.4 Usability
      - 11.1.1.4.2.5 End User

12 Long-Term Injectable Drug Delivery Market Industry Landscape

13 - Key Company Profiles

13.1 Terumo Corp
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Phillips-Medisize
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Gerresheimer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 West Pharmaceutical Services Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Ypsomed Holding AG
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Schott AG
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AptarGroup Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Becton Dickinson and Co
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Owen Mumford Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SHL Medical
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 Glossary
14.2 Research Methodology and Approach
- 14.2.1 Secondary Research
- 14.2.2 Primary Research
- 14.2.3 Market Estimation Approach
  - 14.2.3.1 Supply Side Analysis
  - 14.2.3.2 Demand Side Analysis
- 14.2.4 Research Assumptions and Limitations
- 14.2.5 Currency Conversion
14.3 About The Insight Partners
14.4 Market Intelligence Cloud